Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | MAPK4 | P31152 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659311 | 0.85 | PDGFRB (0.52) | TRPV1PTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL22679920 | 0.85 | TRPV1 (0.47) | TRPV1PTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL22659137 | 0.83 | KCNQ3 (0.47) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL22659842 | 0.83 | MCHR1 (0.51) | TRPV1PTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29406502 | 0.82 | ORAI1 (0.41) | KCNQ1MEN1KMT2ANPC1POLB | |
| SCHEMBL22659840 | 0.82 | ORAI1 (0.41) | KCNQ1MEN1KMT2ANPC1POLB | |
| SCHEMBL22659168 | 0.81 | KLKB1 (0.48) | TRPV1PTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29405937 | 0.81 | KLKB1 (0.48) | TRPV1PTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL22659359 | 0.80 | DGAT2 (0.49) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29405064 | 0.80 | DGAT2 (0.49) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | TRPV1 336/4885PTPN1 3365/4885KCNQ3 4135/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | TRPV1 336/4885PTPN1 3365/4885KCNQ3 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.